CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 70 target
Drug / intervention
Docusate Sodium, Sennoside +1 moredrug
Likely dose
Docusate Sodium, Sennoside 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00902031
NCT00902031N/ACompleted
CompareCT.gov

Randomized, Double-Blind, Placebo-Controlled Trial of Oral Docusate for Preventing/Treating Constipation in Palliative Care Patients.

University of Alberta·interventional·Posted May 14, 2009·Updated Apr 20, 2011

In Brief

A clinical study evaluating Docusate Sodium, Sennoside and Sennoside + Placebo for Constipation and Palliative Care. Completed, enrolled 70 participants across 3 sites.

Detailed Summary

The purpose of this study is to determine if docusate is effective in the treatment of constipation in palliative care patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConstipation, Palliative Care
CountriesCanada
CollaboratorsCollege of Family Physicians of Canada, Covenant Health, Canada, Capital Care

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 14, 2009
Enrollment StartApr 1, 2006
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 17.1 years ago

Interventions

Docusate Sodium, Sennosidedrug

Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days. Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.

Sennoside + Placebodrug

Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days. Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days